AstraZeneca’s Ultomiris (ravulizumab-cwvz) has been approved in the United States as a long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).   The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology. Preventing Relapses by Treating NMOSD NMOSD is a rare...